KERRI B. Anderson’s SEC Form 4 activity over the past year paints a clear picture of a director or executive who is a consistent seller of stock, with no open-market purchases on record. Across 39 total transactions spanning four companies, Anderson has realized approximately $3.09 million in sales while acquiring only about $127,000 in value, almost entirely through compensation grants and option exercises. The selling bias is pronounced: the most recent four trades are all sales, and the largest transactions by dollar value — two $980,000 sales of Labcorp Holdings (LH) stock on July 24, 2025, plus a $132,500 LH sale on July 1, 2025 — cluster in the mid-2025 period. Anderson also sold $408,234 worth of Abercrombie & Fitch (ANF) shares on August 29, 2025, the only significant ANF disposition.
The pattern is not one of aggressive dumping but of steady, periodic liquidation, likely tied to vesting schedules and routine portfolio management. The bulk of the other filings are code “A” grants — compensation awards with no cash exchanged — across SHW (Sherwin-Williams), ANF, LH, and WOR (Worthington Enterprises), with SHW grants recurring quarterly at roughly $10,000 each. Option exercises (code “M”) at ANF and LH in 2026 carry zero reported value, suggesting they were in-the-money conversions that preceded or accompanied sales. Notably, there are no code “P” purchases anywhere in the record, meaning Anderson has not put fresh capital into any of these four companies during the filing window. The most recent activity, a $10,000 SHW grant on July 6, 2026, is purely compensatory, and the absence of any buy-side conviction leaves the overall trajectory firmly tilted toward distribution rather than accumulation.
AI-assisted summary